Imetelstat Induces Leukemia Stem Cell Death in Pediatric Acute Myeloid Leukemia Patient-Derived Xenografts
Open Access
- 30 March 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (7) , 1923
Abstract
Acute myeloid leukemia (AML) in children remains deadly, despite the use of maximally intensive therapy. Because leukemia stem cells (LSCs) significantly contribute to chemoresistance and relapse, therapies that specifically target the LSCs are likely to be more beneficial in improving outcome. LSCs are known to have high telomerase activity and telomerase activity is negatively correlated with survival in pediatric AML. We evaluated the preclinical efficacy of imetelstat, an oligonucleotide inhibitor of telomerase activity in patient-derived xenograft (PDX) lines of pediatric AML. Imetelstat treatment significantly increased apoptosis/death of the LSC population in a dose-dependent manner in six pediatric AML PDX lines ex vivo, while it had limited activity on the stem cell population in normal bone marrow specimens. These results were validated in vivo in two distinct PDX models wherein imetelstat as single agent or in combination with chemotherapy greatly reduced the LSC percentage and prolonged median survival. Imetelstat combination with DNA hypomethylating agent azacitidine was also beneficial in extending survival. Secondary transplantation experiments showed delayed engraftment and improved survival of mice receiving imetelstat-treated cells, confirming the diminished LSC population. Thus, our data suggest that imetelstat represents an effective therapeutic strategy for pediatric AML.Keywords
Funding Information
- Geron (United States) (unnumbered)
- Lisa Dean Moseley Foundation (unnumbered)
- Leukemia Research Foundation of Delaware (unnumbered)
- National Institute of General Medical Sciences (P20GM103446)
- Andrew McDonough B+ Foundation (unnumbered)
- Nemours Foundation (unnumbered)
This publication has 29 references indexed in Scilit:
- Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer CellsCancer Research, 2016
- A Pilot Study of the Telomerase Inhibitor Imetelstat for MyelofibrosisNew England Journal of Medicine, 2015
- Telomerase Inhibitor Imetelstat in Patients with Essential ThrombocythemiaNew England Journal of Medicine, 2015
- Telomerase Inhibition Effectively Targets Mouse and Human AML Stem Cells and Delays Relapse following ChemotherapyCell Stem Cell, 2014
- Telomere length and telomerase complex mutations in pediatric acute myeloid leukemiaLeukemia, 2013
- Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasiaLeukemia, 2012
- Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes in Acute Myeloid LeukemiaJAMA, 2010
- Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemiaProceedings of the National Academy of Sciences, 2009
- Lipid modification of GRN163, an N3′ → P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibitionOncogene, 2005
- Telomerase activity is prognostic in pediatric patients with acute myeloid leukemiaCancer, 2003